Patents by Inventor Dimitrius Karussis

Dimitrius Karussis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-malignant disease treatment with Ras antagonists
    Publication number: 20050119237
    Abstract: Disclosed is a method for inhibiting Ras-induced or mediated proliferation of cells associated with a non-malignant disease, disorder or pathological condition. The method entails administering to a patient a Ras antagonist in an amount effective to inhibit the proliferation. The invention is particularly applicable to diseases characterized by a proliferation of T-cells such as autoimmune disease, e.g., type 1 diabetes, lupus and multiple sclerosis, and pathological states such as graft rejection induced by the presentation of a foreign antigen such as a graft in response to a disease condition (e.g., kidney failure). Other non-malignant diseases characterized by proliferations of cells include cirrhosis of the liver and restenosis. Preferred Ras antagonists are S-trans-trans farnesylthiosalicylic acid (FTS) and structurally related compounds (or analogs) thereof.
    Type: Application
    Filed: June 14, 2004
    Publication date: June 2, 2005
    Applicant: Ramot University Authority for Applied Research & Industrial Development Ltd.
    Inventors: Yoel Kloog, Joab Chapman, Dimitrius Karussis, Rafael Bruck, Shimon Reif, Michael Brownstein
  • Non-malignant disease treatment with Ras antagonists
    Patent number: 6462086
    Abstract: Disclosed is a method for inhibiting Ras-induced or mediated proliferation of cells associated with a non-malignant disease, disorder or pathological condition. The method entails administering to a patient a Ras antagonist in an amount effective to inhibit the proliferation. The invention is particularly applicable to diseases characterized by a proliferation of T-cells such as autoimmune disease, e.g., type 1 diabetes, lupus and multiple sclerosis, and pathological states such as graft rejection induced by the presentation of a foreign antigen such as a graft in response to a disease condition (e.g., kidney failure). Other non-malignant diseases characterized by proliferations of cells include cirrhosis of the liver and restenosis. Preferred Ras antagonists are S-trans-trans farnesylthiosalicylic acid (FTS) and structurally related compounds (or analogs) thereof.
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: October 8, 2002
    Assignee: Ramot University Authority for Applied Research and Industrial Development Ltd.
    Inventors: Yoel Kloog, Joab Chapman, Dimitrius Karussis, Rafael Bruck, Shimon Reif, Michael Brownstein